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Abstract Angiotensin converting enzyme (ACE) and the
Alzheimer’s amyloid precursor protein are cleaved from the
membrane by zinc metalloproteinases termed ACE secretase and
K-secretase, respectively. Tumour necrosis factor-K (TNF-K)
convertase (ADAM 17) is a recently identified member of the
adamalysin family of mammalian zinc metalloproteinases that is
involved in the production of TNF-K and possibly in the cleavage
of other membrane proteins. Using two different cell-free assays
we were unable to detect significant cleavage and secretion of
ACE by TNF-K convertase. In addition, there was a different
effect of three hydroxamic acid-based inhibitors (batimastat,
compound 1 and compound 4) towards TNF-K convertase as
compared to ACE secretase and K-secretase. Thus TNF-K
convertase would appear to be distinct from, but possibly related
to, the secretases that cleave ACE and the amyloid precursor
protein.
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1. Introduction
Numerous integral membrane proteins also exist in a solu-
ble form as a result of a post-translational proteolytic cleav-
age event (reviewed in [1]). Examples of such proteins include
angiotensin converting enzyme (ACE), the Alzheimer’s amy-
loid precursor protein (APP), and tumour necrosis factor-K
(TNF-K). The proteinases responsible for the release of these
membrane proteins have been termed membrane protein sec-
retases, sheddases or convertases. The secretases involved in
the release of distinct membrane proteins have several proper-
ties in common. Many of the activities are zinc metallopro-
teinases, being inhibited by chelating agents and synthetic
hydroxamic acid-based compounds such as batimastat [1].
In addition, the secretase activities are upregulated by phorbol
esters, and cleave within the membrane proximal stalk region
of the substrate protein [1].
ACE is a widely distributed ectoenzyme that occurs both as
the membrane-bound form on the endothelial and epithelial
surfaces of tissues and as a soluble form in plasma and other
body £uids [2]. The secretase that releases ACE from the
membrane is itself an integral membrane protein, localised
to the plasma membrane [3^5]. Recently, we have shown
that the secretase has an absolute requirement for its substrate
(ACE) to be anchored in a membrane for cleavage to occur
[4], a phenomenon that appears to apply to several other
secretases including those responsible for the cleavage of
APP [6,7], Kit ligand [8] and colony-stimulating factor [9].
ACE secretase is inhibited by several hydroxamic acid-based
zinc metalloproteinase inhibitors including batimastat, mari-
mastat and BB2116, with I50 values in the low micromolar
range [4,10].
APP is cleaved by several proteinases termed K-, L- and Q-
secretases [1,11,12]. Cleavage of APP at the N-terminus of the
L-amyloid peptide by L-secretase and at the C-terminus by
one or more Q-secretases constitutes the amyloidogenic path-
way for processing APP. In the non-amyloidogenic pathway,
K-secretase cleaves APP within the L-amyloid peptide, thereby
preventing deposition of the intact amyloid peptide which is a
primary constituent of the senile plaques in brains from Alz-
heimer’s patients. Recently we have shown that K-secretase is
inhibited by a range of hydroxamic acid-based compounds
with a very similar structure activity relationship to that ob-
served with ACE secretase [10]. These two secretases have
several other properties in common. Both enzymes are stimu-
lated by phorbol esters, cleave their respective substrates be-
tween a basic and a hydrophobic residue, and are integral
membrane proteins with a distinctive detergent solubilisation
pro¢le [4^6,13]. Thus, ACE secretase and K-secretase appear
to be the same, or closely related, zinc metalloproteinases.
TNF-K is cleaved from its membrane-bound precursor by
TNF-K convertase [14]. The physiological importance of this
in£ammatory cytokine has led to intense interest in the mech-
anism of its generation, and the potential therapeutic bene¢t
of inhibitors of this process [15]. TNF-K convertase (ADAM
17) has been recently isolated, cloned and sequenced [16,17].
The cDNA encodes a protein of 824 amino acids, consisting
of a multidomain extracellular part, a transmembrane helix
and an intracellular C-terminal tail. The extracellular part
comprises an N-terminal pro-domain, a 259-residue catalytic
domain containing the extended HEXXH zinc binding motif,
and a Cys-rich domain that is composed of a disintegrin-like,
an epidermal growth factor-like and a crambin-like domain.
This domain structure is characteristic of the adamalysin or
ADAMs (a disintegrin and metalloproteinase) family of zinc
metalloproteinases [18,19]. The similarity in properties be-
tween TNF-K convertase and other secretases has led to spec-
ulation that TNF-K convertase may be involved in shedding
other cell-surface proteins, in addition to TNF-K. In the
present study we have investigated whether TNF-K convertase
is able to cleave ACE in two cell-free systems. TNF-K con-
vertase did not signi¢cantly cleave ACE, and the di¡erent
inhibitor pro¢le with three hydroxamic acid-based com-
pounds, indicate that TNF-K convertase is distinct from
ACE secretase and the amyloid precursor protein K-secretase.
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2. Materials and methods
2.1. Materials
Batimastat (BB94) and compounds 1 and 4 were synthesised at
SmithKline Beecham Pharmaceuticals, Harlow, UK. Compound 1
di¡ers from batimastat only by the absence of the thienothiomethyl
substituent adjacent to the hydroxamic acid moiety, while compound
4 di¡ers from compound 1 by the presence of a tertiary amine at its
C-terminus (for structures see [4]). Natural full-length TNF-K conver-
tase and recombinant extracellular domain TNF-K convertase were
provided by Dr R. Black (Immunex Corporation, Seattle, USA).
2.2. Reconstituted secretase assay
The amphipathic, full-length form of ACE was puri¢ed from por-
cine kidney cortex following solubilisation with Triton X-100 in the
presence of 10 mM EDTA by a⁄nity chromatography on lisinopril-
2.8 nm-Sepharose [20]. Amphipathic, full-length ACE was reconsti-
tuted into dimyristoyl phosphatidylcholine vesicles as described pre-
viously [20]. After incubation of the lipid vesicles containing the am-
phipathic form of ACE (5 Wg of protein) with either TNF-K
convertase or trypsin at 37‡C in 10 mM Tris-HCl, pH 7.8, the samples
were subjected to temperature-induced phase separation in pre-con-
densed Triton X-114 [21]. ACE in the resulting detergent-rich and
aqueous phases was quantitated by measurement of enzyme activity
with BzGly-His-Leu as substrate. ACE secretase activity is quanti-
tated as the release of ACE as determined by the amount of ACE
in the ¢nal aqueous phase as a percentage of the total amount of ACE
in both the aqueous and detergent-rich phases.
2.3. Angiotensin converting enzyme assay
ACE enzymic activity was determined with BzGly-His-Leu (5 mM)
as substrate in 0.1 M Tris-HCl, 0.3 M NaCl, 10 WM ZnCl2, pH 8.3.
Reactions were terminated by heating at 100‡C for 4 min, and the
substrate and reaction products resolved and quanti¢ed by reverse-
phase HPLC as described previously [22].
2.4. TNF-K convertase assay
TNF-K convertase was incubated with 833 WM TNF-K7 peptide
(Ac-SPLAQAVRSSSR-NH2 ; provided by Dr R. Black) for 30 min
at 37‡C in 10 mM Tris-HCl, pH 7.8. Following the incubation the
reaction was stopped by heating at 100‡C and the substrate and re-
action products resolved and quantitated by reverse phase HPLC
(Waters Millenium system) with a C18 column using a linear gradient
of 0^50% MeCN in 0.1% tri£uoroacetic acid with detection at 214
nm.
3. Results and discussion
The ability of TNF-K convertase to cleave ACE was as-
sessed using the reconstituted assay system in which a⁄nity
puri¢ed ACE is incorporated into arti¢cial lipid vesicles [4].
Lipid vesicles containing ACE were incubated with either re-
combinant extracellular domain TNF-K convertase or natural
full-length TNF-K convertase (Table 1). The cleavage of ACE
was examined by monitoring the distribution of the enzyme
between the aqueous and detergent-rich phases following
phase separation in Triton X-114. Negligible cleavage of
ACE from the lipid vesicles by either form of TNF-K conver-
tase was observed. In comparison trypsin readily cleaved ACE
from the lipid vesicles (Table 1). For comparison, a detergent-
solubilised porcine kidney microsomal membrane fraction, in
which ACE secretase is present but not puri¢ed, cleaved ACE
in the reconstituted assay with a speci¢c activity of 0.03 ng
ACE cleaved/min/Wg protein [4].
In case there was the requirement for a factor present in
biological membranes that was absent from the arti¢cial lipid
vesicles, the ability of recombinant extracellular domain TNF-
K convertase to cleave and release ACE from porcine kidney
microvillar membranes was examined. Incubation of the mi-
crovillar membranes at 37‡C led to an increase in ACE activ-
ity in the aqueous phase due to the presence of endogenous
secretase activity in the membranes (Table 2) as previously
documented [3]. Addition of recombinant extracellular do-
main TNF-K convertase did not lead to an increase in the
release of ACE from the microvillar membranes above that
due to the endogenous secretase activity (Table 2). Batimastat,
which inhibits both the endogenous secretase [4] and TNF-K
convertase [17], completely inhibited the release of ACE from
the microvillar membranes. The addition of trypsin to the
microvillar membranes led to a signi¢cant increase in the re-
lease of ACE above that due to the endogenous secretase,
indicating that the availability of substrate was not a limiting
factor for the lack of increased cleavage in the presence of
TNF-K convertase. Thus TNF-K convertase was unable to
cleave and release ACE from a biological membrane system.
Previously we have described a structure/activity relation-
ship for a series of hydroxamic acid-based, active site-directed
zinc metalloproteinase inhibitors towards both ACE secretase
[4] and APP K-secretase [10]. Using as substrate a synthetic
peptide based on the cleavage site in pro-TNF [15], the inhib-
itory e¡ect of three hydroxamic acid-based compounds on the
activity of TNF-K convertase was examined (Table 3).
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Table 1
ACE reconstituted into lipid vesicles is not signi¢cantly cleaved by TNF-K convertase
Enzyme ACE cleaved (ng of ACE cleaved/min/Wg enzyme)
Recombinant extracellular domain TNF-K convertase 0.17
Natural full-length TNF-K convertase 0.09
Trypsin 15.88
A⁄nity puri¢ed ACE (5 Wg) was reconstituted into lipid vesicles and then incubated alone or in the presence of recombinant extracellular domain
TNF-K convertase (0.5 Wg), natural full length TNF-K convertase (15.4 ng) or trypsin (1 Wg) for 2 h at 37‡C in 10 mM Tris-HCl, pH 7.8. After the
incubation the samples were subjected to phase separation in Triton X-114 and the resulting aqueous and detergent-rich phases assayed for ACE
activity. Results are representative of two separate experiments each performed in duplicate.
Table 2
TNF-K convertase does not release ACE from kidney microvillar
membranes
Enzyme ACE activity in aqueous
phase (% of total)
No addition 34.9
TNF-K convertase 34.8
TNF-K convertase+batimastat 0.0
Trypsin 61.5
Porcine kidney microvillar membranes (76.2 Wg of protein) prepared
as described previously [24] were incubated alone or in the presence of
recombinant extracellular domain TNF-K convertase (0.5 Wg) or tryp-
sin (7 Wg) for 4 h at 37‡C in 10 mM Tris-HCl, pH 7.8. Batimastat (100
WM) was included where indicated. Following the incubation, samples
were subjected to phase separation in Triton X-114 and the resulting
aqueous and detergent-rich phases assayed for ACE activity. The
results are representative of two separate experiments each performed
in duplicate.
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Although batimastat, compound 1 and compound 4 have very
similar e¡ects on ACE secretase and K-secretase, marked dif-
ferences were observed in the inhibition of TNF-K convertase.
All of the hydroxamate compounds examined were signi¢-
cantly (100^500-fold) more potent against TNF-K convertase
than against the other two secretases, and at a concentration
(100 WM) at which compound 4 failed to inhibit ACE secret-
ase, complete inhibition of TNF-K convertase was observed.
Compound 4 di¡ers from compound 1 only by the presence of
a tertiary amine at its C-terminus (for structures see [4]) ; a
di¡erence that makes compound 4 essentially inactive towards
ACE secretase and K-secretase. The recently determined crys-
tal structure of the catalytic domain of TNF-K convertase
with a hydroxamate compound bound at the active site [23],
revealed that the C-terminus of the inhibitor extends away
from the active site cleft and adopts di¡erent conformations.
It is possible that the active site clefts in ACE secretase and K-
secretase make closer contact with the C-terminus of the in-
hibitor such that an amide H (as in batimastat and compound
1) is critical for e⁄cient binding, whereas replacement of this
group with a bulkier methyl group (as in compound 4) dis-
rupts the interaction.
4. Conclusion
To date the secretases that cleave ACE and APP have not
been identi¢ed. From the present study it would appear, using
two cell-free systems in which the substrate is membrane-
bound, that ACE is not signi¢cantly cleaved by TNF-K con-
vertase. The di¡erence in the e¡ect of hydroxamic acid-based
inhibitors towards TNF-K convertase on the one hand and
ACE secretase and K-secretase on the other, further indicates
that TNF-K convertase is distinct from, but possibly related
to, these other two secretases. Whether ACE secretase and K-
secretase are other members of the adamalysin family of zinc
metalloproteinases awaits their isolation and sequencing.
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Table 3
The e¡ect of inhibitors on TNF-K convertase is di¡erent to that on ACE secretase and APP K-secretase
Inhibitor TNF-K convertase I50 (WM) ACE secretase I50 (WM) K-secretase I50 (WM)
Batimastat 0.019 þ 0.002 1.6b 3.3b
Compound 1 0.037 38.3a 17.9b
Compound 4 0.18 þ 0.08 s 100a s 20b
Natural full length TNF-K convertase (7.7 ng) was incubated in the presence of varying concentrations of the indicated inhibitors with 833 WM
TNF-K7 peptide as described in Section 2. I50 values were determined from at least two independently determined inhibition curves. aData from [4].
bData from [10].
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